We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Visceral leishmaniasis

    Tech/Science

    New Hope for Treating Visceral Leishmaniasis

    Discover the latest breakthrough in the fight against visceral leishmaniasis, a deadly infectious disease affecting millions worldwide. Professor Simona Stäger and her team have uncovered a new immune mechanism that could lead to a novel therapeutic strategy. Learn more about this groundbreaking research and its potential impact on treating this life-threatening illness.

    Posted on Jhon
    Health

    LifeArc and FIND provide 7.8 million U.S. dollars to support Kenya’s fight against visceral leishmaniasis

    Two international health charities, LifeArc and FIND, have announced a funding support of 7.8 million U.S. dollars to bolster Kenya’s efforts to eliminate visceral leishmaniasis, a fatal vector-borne disease also known as kala-azar among children. The funding aims to improve the diagnosis and treatment of the neglected tropical disease among children in Kenya. Visceral leishmaniasis is a parasitic disease found in marginalized parts of Africa, affecting mainly children and being fatal in over 95 percent of cases if left untreated. The disease, caused by parasites spread by sandflies, affects internal organs and presents symptoms such as weight loss, and enlargement of the spleen and liver. The funding from international charities is expected to help Kenya improve community awareness and enhance the capacity of local health facilities to conduct faster diagnosis and treatment of visceral leishmaniasis. The initiative is targeted for elimination by the World Health Organization (WHO) by 2030, and strategic partnerships are emphasized to boost the elimination of kala-azar.

    Posted on Jhon